Roche
Regeneron’s High-Dose Eylea Launch Takes Off, Rivals Roche’s Vabysmo
Roche’s increased sales for its extended-release treatment for macular degeneration, Vabysmo, indicate that consumers are willing to try new therapies. ...
Roche’s TIGIT Therapy: ESMO Reveals Ongoing Commitment
Roche is taking a steadfast position in the realm of TIGIT-class therapies, even in the face of fluctuating data and ...
Roche, Biogen end patent dispute over Actemra biosimilar
Roche has swiftly resolved a patent infringement lawsuit it initiated against Biogen in July. The legal dispute centered around Biogen’s ...
Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy
Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...
Roche unveils its blood cancer strategy after COVID-19 boost
While Roche has seen a decline in COVID-19 drug sales after the pandemic boom, the company is experiencing a resurgence ...
PTC sells royalty rights of SMA drug Evrysdi to Royalty Pharma for $1.5B
As part of its cost-cutting efforts and in response to potential challenges in the European market, PTC Therapeutics is taking ...
Roche abandons oral drug for eye disease after phase 2 failure, shifts focus from solid tumor bispecifics
Roche’s ambitious quest to develop an oral treatment for diabetic retinopathy has faced a setback, as the company decided to ...
Neurology patient groups rate pharma higher, but some big players lose rank
The pharmaceutical industry’s reputation among neurology patient groups has undergone a notable transformation, marking the third consecutive year of positive ...
SpliceBio and Roche’s Spark Therapeutics team up for eye disease gene therapy
SpliceBio Initiates $216 Million Collaboration with Roche’s Gene Therapy Unit to Pave the Way for Innovative Inherited Retinal Disease Treatment ...
Roche partners with Monte Rosa to develop molecular glue drugs for cancer
In a dynamic move, Roche has forged its second major agreement in the realm of molecular glue technology, this time ...
Roche’s BTK inhibitor shows potential to cross blood-brain barrier in MS trial
Roche is touting its multiple sclerosis (MS) drug as a potential game-changer in the field, asserting that it has achieved ...
Roche’s Ocrevus shows similar efficacy and safety in subcutaneous and intravenous forms
Roche’s innovative subcutaneous adaptation of its highly-regarded multiple sclerosis (MS) medication, Ocrevus, has achieved a significant breakthrough in a pivotal ...
Roche’s Vabysmo Preserves RVO Patients’ Vision with 4-Month Treatment Intervals in Phase III Trials
Roche has unveiled promising long-term findings from the global phase III BALATON and COMINO trials, which investigated the extended treatment ...
FDA Approves Biogen’s Biosimilar, Challenging Roche’s Actemra Dominance in the Market
Biogen has achieved a remarkable milestone while contemplating the future of its biosimilars division. The company proudly announced that its ...
Venclexta fails to meet primary endpoint in multiple myeloma trial
AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...
Roche and Ionis expand partnership with new RNA programs for Alzheimer’s and Huntington’s
Roche, in its quest to find effective treatments for Alzheimer’s diseases after the setbacks of gantenerumab, has reaffirmed its commitment ...
Roche denounces counterfeit Avastin that caused blindness in Pakistan
Following a distressing incident in which several diabetic patients were administered a counterfeit version of Roche’s Avastin, resulting in the ...
Roche wins patent appeal over Hemlibra, its hemophilia A drug, against Takeda’s Baxalta
In a patent dispute revolving around two competing hemophilia medications, Roche’s Genentech unit has achieved its second consecutive victory. Following ...
Roche fined for serious breach of marketing code by failing to disclose safety data
Roche, a prominent pharmaceutical company, is under scrutiny for omitting vital safety details from a webpage dedicated to dosing information ...
Genentech and PeptiDream expand peptide collaboration to explore radiopharmaceuticals for cancer
Japanese biotech firm PeptiDream continues to attract significant interest from major pharmaceutical companies. Genentech, a long-term partner, has entered into ...
Genentech and Orionis Biosciences team up to discover molecular glue drugs for oncology and neurodegeneration
Genentech, a subsidiary of Roche, is aggressively expanding its partnered portfolio into cutting-edge areas of research and development. Following a ...
Lonza CEO Ruffieux quits after less than a year, chairman steps in
Lonza, the Swiss Contract Development and Manufacturing Organization (CDMO), is once again on the hunt for a new CEO, marking ...
Roche’s subcutaneous Tecentriq faces FDA setback due to manufacturing updates
Roche may experience a delay in the FDA decision for its subcutaneous version of the cancer immunotherapy Tecentriq, as it ...
Roche’s $310 Million Gamble On Alnylam Pays Off As Hypertension Drug Shows Promise In Phase 2
Roche’s recent investment of $310 million into metabolic therapy is yielding positive results, as its collaboration with Alnylam in the ...
Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
Outlook’s eye drug Lytenava fails to win FDA approval, despite positive trial
Outlook Therapeutics has been working on a reformulated version of Roche’s cancer drug Avastin for the treatment of certain eye ...
Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light
Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...
Roche’s Evrysdi Illuminates Hope: EC Expands Approval for SMA Infants
To provide a brighter future for infants battling spinal muscular atrophy (SMA), Roche has unveiled a momentous development. The European ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
Horizon Surpasses Roche in Rare Disease Reputation, While Pfizer’s Standing Declines
Horizon Therapeutics continues to collect accolades as it progresses toward its acquisition, with rare disease organizations now recognizing its excellence. ...
